{"schema_version":"1","generated_at":"2026-11-02T22:26:28.937Z","data_as_of":null,"url":"https://www.findmykol.com/kol/shalin-kothari","json_url":"https://www.findmykol.com/kol/shalin-kothari/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"shalin-kothari","name":"Shalin Kothari","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Yale Cancer Center","institution_url":"https://www.findmykol.com/institution/yale-school-of-medicine","city":"New Haven","state":"CT","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1417391525","orcid":"0000-0001-9268-0354","openalex":"A5069873622"},"summary":"Shalin Kothari is an Oncology physician affiliated with Yale Cancer Center. OpenAlex indexes 77 publications with 427 citations (h-index 9).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":77,"cited_by_count":427,"h_index":9,"latest_activity_year":2026,"source":"works"},"payments":{"company_count":3,"program_years":{"first":2021,"last":null},"rows_total":0,"shown":0,"withheld":0,"rows":[],"record_url":"https://openpaymentsdata.cms.gov/search?query=1417391525","source":"payments"},"prescribing":{"data_year":2023,"areas_total":3,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":52.6,"classes_total":2,"classes":[{"class":"Kinase inhibitor","setting":"prescribed","share_pct":37.1,"drugs":[{"name":"Brukinsa","share_pct":50},{"name":"Imbruvica","share_pct":50}],"max_beneficiaries":null},{"class":"BCL-2 Inhibitor","setting":"prescribed","share_pct":15.5,"drugs":[{"name":"Venclexta","share_pct":100}],"max_beneficiaries":null}]},{"area":"Dermatology","share_pct":29.9,"classes_total":1,"classes":[{"class":"Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor","setting":"prescribed","share_pct":29.9,"drugs":[{"name":"Acyclovir","share_pct":100}],"max_beneficiaries":11}]},{"area":"Nervous system","share_pct":17.5,"classes_total":1,"classes":[{"class":"Phenothiazine","setting":"prescribed","share_pct":17.5,"drugs":[{"name":"Prochlorperazine Maleate","share_pct":100}],"max_beneficiaries":12}]}],"care_setting":{"dominant":"facility","data_year":2023,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Targeting β-catenin degradation with GSK3β inhibitors induces cell death in acute lymphoblastic leukemia","year":2026,"journal":"Nature Cancer","source_url":"https://doi.org/10.1038/s43018-025-01093-z","status":"verified"},{"title":"Comparison of Outcomes With Novel Versus Traditional Chemotherapy Regimens for Relapsed and Refractory Classical Hodgkin Lymphoma","year":2026,"journal":"Clinical Lymphoma Myeloma & Leukemia","source_url":"https://doi.org/10.1016/j.clml.2026.01.018","status":"verified"},{"title":"Abstract CT268: Phase 1 study of ARV-393, a PROTAC BCL6 degrader, as monotherapy in patients with advanced non-Hodgkin lymphoma (NHL) or combined with glofitamab in patients with diffuse large B-cell lymphoma (DLBCL)","year":2026,"journal":"Cancer Research","source_url":"https://doi.org/10.1158/1538-7445.am2026-ct268","status":"verified"},{"title":"Phase 1 study of ARV-393, a PROTAC BCL6 degrader, as monotherapy in patients with advanced non-Hodgkin lymphoma (NHL) or combined with glofitamab in patients with diffuse large B-cell lymphoma (DLBCL).","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps7103","status":"verified"},{"title":"Impact of memory T cells on SARS-CoV-2 vaccine response in hematopoietic stem cell transplant","year":2025,"journal":"PLoS ONE","source_url":"https://doi.org/10.1371/journal.pone.0320744","status":"verified"}],"source":"works"},"similar":[{"name":"Ian Krop","slug":"ian-krop","institution":"Yale Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/ian-krop","json_url":"https://www.findmykol.com/kol/ian-krop/profile.json"},{"name":"Harriet Kluger","slug":"harriet-kluger","institution":"Yale Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/harriet-kluger","json_url":"https://www.findmykol.com/kol/harriet-kluger/profile.json"},{"name":"Stephanie Halene","slug":"stephanie-halene","institution":"Yale Cancer Center","specialty":"Hematology","url":"https://www.findmykol.com/kol/stephanie-halene","json_url":"https://www.findmykol.com/kol/stephanie-halene/profile.json"},{"name":"John Kunstman","slug":"john-kunstman","institution":"Yale Cancer Center","specialty":"Surgical Oncology","url":"https://www.findmykol.com/kol/john-kunstman","json_url":"https://www.findmykol.com/kol/john-kunstman/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}